Iván R. González: IHC Panel Defines Pulmonary Carcinoids Subgroups and Targets
Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared on X:
“An immunohistochemical panel using OTP/ASCL1/HNF1A classifies pulmonary carcinoids into clinically distinct subgroups, uncovering potential therapeutic targets like SSTR2A and DLL3. These insights pave the way for personalized approaches and demand further validation in prospective studies.
1. Subgroups defined by OTP/ASCL1/HNF1A (IHC):
A1: OTP/ASCL1/HNF1A
A2: OTP/ASCL1/HNF1A
B: OTP/ASCL1/HNF1A
2. Key clinical and therapeutic traits:
A1: Older patients, peripheral tumors, DLL3 high, SSTR2A low, higher neuroendocrine cell hyperplasia.
A2: Younger patients, central tumors, DLL3 low, SSTR2Ah high.
B: Higher recurrence, male predominance.”
Authors: D.J.G. Leunissen, L. Moonen, J.H. von der Thüsen, M.A. den Bakker, L.M. Hillen, T.J.J. van Weert, A. zur Hausen, T.P.P. van den Bosch, L.M.V. Lap, R.A. Damhuis, N.L. Reynaert, Esther C. van den Broek, PALGA group, L. Fernandez-Cuesta, M. Foll, N. Alcala, A. Sexton Oates A.-M.C. Dingemans, E.J.M. Speel, J.L. Derks.
More posts featuring Iván R. González on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023